Ultrasound to Facilitate Stone Passage
Launched by UNIVERSITY OF WASHINGTON · Mar 10, 2021
Trial Information
Current as of July 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to help people pass kidney stones using ultrasound technology. Instead of needing anesthesia, the researchers want to see if they can safely break up and move the stones using ultrasound waves. This trial is not yet recruiting participants, but it aims to find out if this method can be an effective treatment for those with certain types of kidney stones.
To be eligible for this trial, participants must be adults between the ages of 65 and 74 who have at least one kidney stone measuring between 2 mm and 7 mm. However, some individuals won't be able to join, such as those under 18, pregnant women, or anyone with specific health issues that might complicate the procedure. If selected, participants can expect to undergo the ultrasound treatment and will need to attend follow-up appointments to monitor their progress. It's an exciting opportunity for those struggling with kidney stones to potentially benefit from a less invasive treatment option.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Individuals presenting with at least one kidney stone
- • Stone with maximum dimension \> 2 mm and ≤ 7 mm as determined by clinical imaging
- • Individuals with SCI - (Phase 2b only)
- Exclusion Criteria:
- • Individuals under 18 years of age
- • Individuals who are pregnant or who are trying to get pregnant
- • Prisoners
- • with cognitive impairment that would limit their ability to comprehend their role in consent or participation.
- • Individuals who are unable to read or understand English
- • Individuals who are unable or unwilling to participate in follow up activities
- • Individuals who cannot be positioned for ultrasound imaging
- • Individuals with uncorrected bleeding disorders or coagulopathies
- • Individuals receiving anticoagulants and who are unable or not willing to temporarily cease the medication for the investigational procedure
- • Individuals with a calcified abdominal aortic aneurysm or calcified renal artery aneurysm ipsilateral to the renal stone targeted by the investigational procedure
- • Individuals with a solitary kidney
- • Individuals with an uncorrected urinary tract obstruction
- • Individuals with an untreated infection
- • Individuals with a comorbidity risk which, at the discretion of the physician, would make the patient a poor candidate for the investigational procedure
- • Individuals who have received two previous investigational procedures for the same stone target
- • Individuals who have undergone the investigational procedure within the last 21 days or still have unresolved AEs from a previous investigational procedure.
About University Of Washington
The University of Washington (UW) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a robust network of interdisciplinary teams, UW fosters collaboration among top-tier researchers, clinicians, and healthcare professionals, aiming to translate scientific discoveries into impactful treatments and interventions. The university is dedicated to ethical research practices and participant safety, ensuring rigorous adherence to regulatory standards in all clinical trials. Through its state-of-the-art facilities and extensive expertise, UW strives to address pressing health challenges and improve patient outcomes on a local and global scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seattle, Washington, United States
Seattle, Washington, United States
Carmel, Indiana, United States
Patients applied
Trial Officials
Jonathan Harper, MD
Principal Investigator
University of Washington
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials